

# Trastuzumab Biosimilars Market Size, Share And Growth Analysis For 2023-2032

*The Business Research Company's Trastuzumab Biosimilars Global Market Report 2023 – Market Size, Trends, And Global Forecast 2023-2032*

LONDON, GREATER LONDON, UK, January 20, 2023 /EINPresswire.com/ -- The Business Research Company's global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032



The Business  
Research Company

Trastuzumab Biosimilars Global Market Report 2023 – Market Size, Trends, And Global Forecast 2023-2032

The Business Research Company's "Trastuzumab Biosimilars Global Market Report 2023" is a comprehensive source of information that covers every facet of the trastuzumab biosimilars

market. As per TBRC's trastuzumab biosimilars market forecast, the [trastuzumab biosimilars market size](#) is predicted to reach a value of \$8.86 Billion by 2027, rising at a significant annual growth rate of 27.4 percent through the forecast period.



The Business Research Company's global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032"

*The Business Research  
Company*

The growth in the trastuzumab biosimilars market is due to the rising prevalence of breast and gastric cancer. North America region is expected to hold the largest trastuzumab biosimilars market share. Major players in the trastuzumab biosimilars market include Amgen Inc., Pfizer Inc., Samsung Bioepis, Merck & Co., Biocon Limited.

Learn More On The Trastuzumab Biosimilars Market By Requesting A Free Sample (Includes Graphs And Tables):

<https://www.thebusinessresearchcompany.com/sample.aspx?id=3400&type=smp>

Trending Trastuzumab Biosimilars Market Trend

Major players are continuously focusing on launching new products in the untapped regions, which is shaping the market for trastuzumab biosimilars. The companies operating in the

trastuzumab biosimilars market are undergoing various strategic initiatives such as new product development, partnerships, and geographical and product portfolio expansion to maintain their competitive position in the market and better serve the needs of the customers. For instance, in February 2020, Pfizer launched trastuzumab biosimilar to Herceptin, Trazimera in the USA. Trazimera is available for the treatment of human epidermal growth factor receptor 2 (HER2) metastatic gastric and breast cancer. Furthermore, in April 2020, Merck announced the launch of a Biosimilar of Herceptin (trastuzumab)- ONTRUZANT(trastuzumab-dttb). ONTRUZANT is available in the USA for approximately \$1,325 and \$3,709 for the 150 mg single-dose and 420 mg multiple-dose vial, respectively.

### Trastuzumab Biosimilars Market Segments

- By Product: Ogivri, Herzuma, Ontruzant, Trazimera, Other Products
- By Indication: Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Other Indications
- By Distribution Channel: Hospital Pharmacy, Online Pharmacy
- By Geography: The global trastuzumab biosimilars market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.

Read more on the global trastuzumab biosimilars market report at:

<https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report>

Trastuzumab biosimilar refers to a HER2-targeted therapy drug that is designed to treat early and metastatic HER2-positive breast cancers. Trastuzumab biosimilar is a monoclonal antibody that binds to the human epidermal growth factor receptor 2 (HER2)/neu receptor and renders it inactive

Trastuzumab Biosimilars Global Market Report 2023 from TBRC covers the following information:

- Market size data for the forecast period: Historical and Future
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Trastuzumab Biosimilars Global Market Report 2023 by The Business Research Company is the most comprehensive report that provides insights on trastuzumab biosimilars global market size, drivers and trends, trastuzumab biosimilars global market major players, competitors' revenues, market positioning, and trastuzumab biosimilars global market growth, trastuzumab biosimilars market outlook across geographies. The trastuzumab biosimilars market report helps you gain in-depth on opportunities and strategies. Companies can leverage the data in the trastuzumab biosimilars insights and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:

Biosimilars Global Market Report 2023

<https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report>

Rituximab Biosimilars Global Market Report 2023

<https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report>

Adalimumab, Infliximab And Etanercept Biosimilars Global Market Report 2023

<https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilar-global-market-report>

About [The Business Research Company?](#)

The Business Research Company has published over 3000+ detailed industry reports, spanning over 3000+ market segments and 60 geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: [info@tbrc.info](mailto:info@tbrc.info)

Check out our:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

Twitter: [https://twitter.com/tbrc\\_info](https://twitter.com/tbrc_info)

Facebook: <https://www.facebook.com/TheBusinessResearchCompany>

YouTube: [https://www.youtube.com/channel/UC24\\_f10rV8cR5DxICpgmyFQ](https://www.youtube.com/channel/UC24_f10rV8cR5DxICpgmyFQ)

Blog: <https://blog.tbrc.info/>

Healthcare Blog: <https://healthcareresearchreports.com/>

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/612340830>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.